참고문헌
- A. Terada, S. Naruto, K. Wachi, S. Tanaka, Y. Iizuka and E. Misaka, "Synthesis and anti-inflammatory activity of [(cysloalkylmethyl) phenyl]acetic acid and related compounds," Journal of Medicinal Chemistry, 27, 212-216 (1984).
- T. Amako, N. Takagish, T. Hiruzaki, Y. Sugioka, K. Takagish and K. Suzuki, "Evaluation of clinical effect of loxoprofen on cervicobrachial syndrome and perathritis of the shoulder," Rinsho To Kenkuy, 62, 214-229 (1985).
- T. Aoki, S. Sugawara, T. Hoshino and M. Yamamoto, "Evaluation of elinical effect of loxoprofen on osteoarthritis of the knee," Igaku No Yyumi, 136, 983-1001 (1986).
- M. Igarashi, N. Ogawa and T. Nobunaga, "Double blind evaluation comparing CD-600 (loxoprofen sodium) and indomethacin in the treatment of rheumatoid arthritis," Ryumachi, 25, 61-72 (1985).
- E. Misaka, T. Yamaguchi, T. Iizuka, K. Kamoshida, T. Kojima, K. Kobayashi, Y. Endo, Y. Misawa, S. Kobayashi and K. Tanaka, "Antiinflammatory antipyretic and analgesic activities of a new antiinflammatory agent: sodium-2[4-(2-oxocyclopentan-1-1-methly) phenyl]propionate dehydrate (CS-600)" Pharmacometrics, 21, 753-771 (1981).
- R. Denis, S. Myriam, S. Angela, O. Marc, A. M. Joseph and S. L. Chun, "Evaluation of loxoprofen and its alcohol metabolites for potency and selectivity of inhibition of cyclooxygenase-2," Bioorganic & Medicinal Chemistry Letters, 14, 1201-1203 (2004).
- T. S. Kim and I. K. Chun, "Formulation and evaluation of loxoprofen plasters," The journal of applied pharmacology, 9, 298-306 (2001).
- A. F. Kydonieus, "Fundametal of transdermal drug delivery: in transdermal delivery of drugs," CRS Press, 1, 3-28 (1987).
- R. H. Guy, "Current status and future prospects of transdermal drug delivery," Pharmaceutical research, 13, 1765-1769 (1996).
- T. K. Ghosh and W. R. Pfister, "Transdermal and topical delivery systems: An overview and future trends: in transdermal and topical drug delivery system," Interpharm press, Inc., 1-32 (1997).
- Y. M. Chien, "Advances in transdermal systemic medication: in transdermal controlled systemic medication, Marcel Dekker. Inc., 1-21 (1987).
- H. M. Wolff, "Optimal process design for the manufacture of transdermal drug delivery systems," Pharmaceutical Science & Technology today, 3, 173-181 (2000).
- H. Seo, S. Y. Jeung, J. S. Park, B. C. Shin, S. J. Hwang and S. H. Cho, "The effect of enhancer on the penetration of indapamide through hairless mouse skin," Journal of Korean Pharmaceutical Sciences, 37, 237-242 (2007).